A major potential problem of autologous transplantation in the treatment of advanced malignancy is the infusion of tumor cells. A multi-institutional study of purified CD34-selected peripheral blood progenitor cell (PBPC) transplantation was conducted in 37 patients with advanced multiple myeloma receiving myeloablative chemotherapy. Fourteen days after intermediate-dose cyclophosphamide, prednisone, and granulocyte colony-stimulating factor (G-CSF), a median of 3 (range, 2 t o 5) 10-L leukaphereses yielded 9.8 x 108/kg (range, 3.7 t o 28.3) mononuclear cells. The adsorbed (column-bound) fraction contained 5.9 x lo6 cells/kg (range, 1.6 to 25.5) with 4.65 x lo6 CD34 cells/kg (range, 1.2 t o 23.3).
A major potential problem of autologous transplantation in the treatment of advanced malignancy is the infusion of tumor cells. A multi-institutional study of purified CD34-selected peripheral blood progenitor cell (PBPC) transplantation was conducted in 37 patients with advanced multiple myeloma receiving myeloablative chemotherapy. Fourteen days after intermediate-dose cyclophosphamide, prednisone, and granulocyte colony-stimulating factor (G-CSF), a median of 3 (range, 2 t o 5) 10-L leukaphereses yielded 9.8 x 108/kg (range, 3. Using Poisson distribution analysis of positive polymerase chain reactions with patient-specific complementarity-determining region 1 (CDR1) and CDR3 Ig-gene primers, tumor was detected in leukapheresis products from 8 of 14 unselected patients and ranged from 1.13 x 10' t o 2.14 x 10' malignant celldkg. After CD34 selection, residual tumor was ESPITE THE SENSITIVITY of multiple myeloma to alkylator-based chemotherapy, the disease remains uniformly fatal with a median survival of 30 months using standard drug regimens.' Consequently, dose-intensive chemotherapy with marrow transplantation has been used in the hopes of inducing complete remission and prolonged progression-free s u r v i~a l .~-~ Although allogeneic transplantation may be curative for some patients,8 most cannot receive this therapy because of advanced age at presentation and subsequent high treatment-related mortality. As a result, several large trials of high-dose chemotherapy and autologous bone marrow transplantation (ABMT) have been reported for patients with advanced multiple myel~ma.~"' Initial patients were eligible for treatment based on resistance to conventional chemotherapy and although cytoreduction was achieved, progression-free survival was b~ief.~.','~ Favorable prognostic factors for sustained response included chemotherapy-sensitive disease and shorter duration of primary treatment. Based on these results, current trials of ABMT, which include recently diagnosed patients with chemother-detected in only three patients' products. Overall, a greater than 2.7-t o 4.5-log reduction in contaminating multiple myeloma cells was achieved. CD34 PBPCs were infused 1 day after busulfan (14 mglkg) and cyclophosphamide (120 mg/ kg), and granulocyte-macrophage colony-stimulating factor was used until hematologic recovery. The median time to both neutrophil and platelet recovery was 12 days (range, 11 t o 16 days and 9 t o 52 days, respectively). The median number of erythrocyte and platelet transfusions was 7 (range, 2 t o 37) and 3 (range, 0 t o 85). respectively. Patients receiving fewer than 2 x lo6 CD34 cells/kg had significantly prolonged neutropenia, thrombocytopenia, and an increased red blood cell and platelet transfusion requirement. Thus, CD34 selection of PBPCs markedly reduces tumor contamination in multiple myeloma and provides effective hematopoietic support for patients receiving myeloablative therapy.
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apy-responsive disease, have achieved high response rates and improved long-term myeloma-free survival." In a recent study of untreated intermediate-to high-stage multiple myeloma, patients assigned to high-dose chemotherapy and BM transplantation achieved complete response and progressionfree survival that was statistically significantly better than that achieved by patients assigned to conventional chemotherapy." A potential problem, unresolved by the use of autologous BM support, is the presence of clonogenic plasma cells in the BM product.
One approach to improve the efficacy of autologous transplantation in multiple myeloma has been through the use of autologous peripheral blood progenitor
In a previous study, we showed that peripheral blood progenitor cells effectively restore hematopoiesis after high-dose chemotherapy,I6 but this product may also be contaminated with clonogenic multiple myeloma cell^.'^"' Thus, although effective as a source of hematopoietic support, tumor contamination exists in mobilized peripheral blood and may, like BM, contribute to early relapse.
A way to reduce the risk of tumor cell contamination in the autograft is through purification of the progenitor cell material. This may be achieved either by purging with a battery of B-cell antigens" or by positive selection for hematopoietic progenitor cells.20~z1 To improve upon the results we achieved using peripheral blood progenitor cells, we evaluated a system of positive progenitor cell selection. The CEPRATE system (Cellpro, Bothell, WA) is a continuousflow column-selection system that relies on the high affinity between avidin and biotin to select antibody-labeled hematopoietic progenitor cells.22~2' The positive selection of cells expressing the CD34 antigen has been used to provide a source of hematopoiesis with a minimal likelihood of reinfusing tumor cells and has been used in clinical studies of BMT for breast carcinoma and other malignancies." In the present study, we used the CEPRATE column to select for purified peripheral blood progenitor cells to support patients receiving myeloablative preparative chemotherapy for adBlood, VOI 86, NO 1 (July I), 1995: PP 390-397
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vanced-stage multiple myeloma, and defined a threshold dose required for sustained engraftment.
To determine residual myeloma cell contamination in the leukapheresis and CD34-selected stem-cell products, we used a novel approach to quantify tumor cell contamination. The Ig heavy-chain sequence can be used as a tumor-specific marker in multiple myeloma because of the unique rearrangements of multiple Ig heavy-chain variable (VH), diversity, and joining-region (JH) gene segmentsz4 Further sequence specificity is generated by the insertion of nongermline nucleotidesz5 and the process of somatic mutation.*'j In multiple myeloma, somatic mutation occurs frequently especially in the unique regions of the VH sequences that are termed the complementarity-determining regions (CDRS).~'.~~ Using a PCR assay with patient-specific CDR primers, tumor contamination was assessed in the leukapheresis product before and after CD34 selection. Quantitative determination was achieved using Poisson distribution analysis of positive polymerase chain reactions (PCRs).
MATERIALS AND METHODS
Thirty-seven subjects, 34 to 65 years old (median, 51 years), with multiple myeloma were consecutively enrolled from July 1993 to September 1994. Data were analyzed as of September 28, 1994 . The study design was approved by the Institutional Review boards of all participating institutions and by the Food and Drug Administration under an investigational device exemption (IDE); all patients gave written informed consent to participate.
The diagnosis of multiple myeloma was made using the criteria and staging of Dune and Salmon.29 Patients were entered if they had evidence of advanced multiple myeloma characterized by one of the following features at diagnosis or thereafter: (1) serum IgG greater than 5 g/dL, IgA greater than 3 g/dL, or urine M component greater than 4 g/24 hours; (2) osteolytic bone lesions or radiographic evidence of diffuse osteoporosis; and (3) P2-microglobulin greater than 3 m@. Patients with nonsecretory myeloma were eligible if there was evidence of extensive marrow plasmacytosis. Patients with major cardiac, pulmonary, gastrointestinal, neurologic, or hepatic disease, serum creatinine greater than 2 mg/dL, age greater than 70 years, or Karnofsky performance status less than 70% were excluded. Patients were also excluded from study for disease defined as refractory to conventional chemotherapy or initially responsive and subsequently progressive on chemotherapy. Patients who had received more than 1 year of alkylator-based Chemotherapy, regardless of disease response, were also ineligible for entry.
Cytapheresis and cryopreservation. Autologous blood progenitor cells were procured after treatment with 2.5 g cyclophosphamide intravenously on day 0, 2 mgkg prednisone orally daily for 4 days (days 0 to 3), and 10 ygkg granulocyte colony-stimulating factor (G-CSF; Amgen, Thousand Oaks, CA) subcutaneously daily starting 1 day after cyclophosphamide.16 Blood progenitor cell apheresis was begun 14 days after cyclophosphamide treatment. Continuous flow leukapheresis was performed with a Cobe Spectra (Cobe, Lakewood, CO). Blood volume processed per run was 10 L at a flow rate of 50 to 70 mL/minute. After this procedure, mononuclear cells were collected and incubated with biotinylated antibody 12-8 (a CD34 antibody) in RPM1 with 0.1% human serum albumin and washed in phosphate-buffered saline (PBS) to remove unbound antibody." The antibody-treated cells were passed successively through a 15 X 2.5 cm Chromaflex column containing 20 mL avidin-biogel until a minimum of 1.0 X IO6 CD34' cellskg were obtained. Cells were cryopreserved in 10% dimethyl sulfoxide by control-rated freezing and stored in the gas phase of liquid nitrogen. A back-up BM harvest sample was cryopreserved in all patients.
CD34 enumeration. Cell counts were performed using a Coulter counter (Coulter Electronics, Hialeah, FL). A total of 0.5 to 1 X IO6 cells were obtained from the leukapheresis product, the flow-through fraction from the CEPRATE column, and from the adsorbed fraction. Cells were incubated on ice in the dark for 30 minutes with 20 yL of anti-CD34 monoclonal antibody (MoAb; HPCA2) conjugated with phycoerythrin (Becton Dickinson, Palo Alto, CA) or the appropriate isotype control (murine IgGl conjugated with phycoerythrin) (Becton Dickinson). Samples were run on a FACScan flow cytometer (Becton-Dickinson) and 50,000 events were acquired. Data were analyzed using Lysis I1 software (Becton Dickinson). Dead cells were excluded on the basis of forward-and side-scatter analysis. CD34' cells were defined with histogram analysis using the whole live-cell population. Analysis gates were set using the CD34 bright cluster obtained after immunoadsorption. The percentage positive cells in the isotype control were subtracted from the CD34' percentage to give the final percentage of CD34+ cells.
Conditioning regimen for transplantation and maintenance. Busulfan (0.875 mgkg orally four times daily for 4 days on days -7 to -4) and cyclophosphamide (60 mgkg intravenously over 1 hour daily for 2 days on days -3 and -2) were given to all patients." Bladder imgation with normal saline was infused at 1,000 mL/h at the start of cyclophosphamide and was continued for 24 hours after the last dose; mesna was not used. Patients with neutrophils less than 0.5 x 109/L were placed in reverse isolation in single rooms and received nystatin and either norfloxacin or ciprofloxacin. Those with a temperature greater than 38.5"C received imipenem or cefoperazone-sulbactam or other broad-spectrum antibacterial antibiotics. Patients with documented or suspected fungal infection received either empiric amphotericin B or fluconazole. Pentoxifylline was not routinely used. Random or single donor platelet transfusions were given to maintain platelets 2 10 X 1 0 y L Red blood cells were transfused to maintain a hematocrit 2 27%. Forty-eight hours after completing pretransplant conditioning, purified peripheral blood progenitor cells were rapidly thawed and given intravenously, after which all patients received daily 500 yg granulocyte-macrophage colony-stimulating factor (GM-CSF Leukine, Immunex, Seattle, WA) intravenously or subcutaneously until neutrophil recovery (defined as absolute neutrophil count [ANC] greater than 1.000 for 3 consecutive days). Patients who achieved a complete or partial remission after the autologous transplantation received a interferon subcutaneously (3 X IO6 IU/m2 three times per week as tolerated) and decadron orally (20 mg/mz daily for 4 days every 4 weeks) beginning 100 days after transplantation and continued for 1 year or until there was evidence of progressive disease.
Response criteria. Patients surviving greater than 1 month posttransplantation were evaluated for response by skeletal radiographs, urine and serum electrophoresis, BM biopsy and serum creatinine, albumin, and P2-microglobulin. These were done pretransplantation and monthly for 4 months and then every 2 months thereafter or until disease progression or relapse. Complete remission was defined as normal BM cellularity, less than 5% plasma cells, no paraprotein in serum and urine by immunoelectrophoresis or immunofixation, and no evidence of progressive bony lesions. Partial remission was defined as a 275% reduction from diagnosis of BM plasmacytosis and serum or urine paraprotein levels, without progressive bony lesions. A minimal response was defined as any reduction in BM plasmacytosis with a reduction in serum or urine paraprotein by less than 75%. Disease progression was defined as the day when BM recurrence and/or new lytic bone disease on radiograph and progressive M component (>25% increase) were detected.
Survival data were computed from the transplantation day. Comparisons of patient features were performed using the Wilcoxon rank sum test." Comparison of the frequency of freedom-from-progression and survival between groups was made with the Fisher's exact test.31 Comparison of means were calculated by chi-square test. Patients were analyzed for survival and progression-free survival from the time of transplantation using the product-limit method of Kaplan and Meier." Summary estimates include actuarial survival fractions at 95% confidence intervals. Analyses were performed using the BMDP statistical pa~kage.~' P values were two-sided throughout.
Sample preparation for tumor detection. Autograft tumor contamination was assessed in 14 of 37 patients transplanted. To determine the Ig gene sequence expressed by the myeloma cells in each patient, total RNA was extracted" from BM mononuclear cells isolated after density centrifugation. The earliest BM specimen obtained from each patient was used for this initial procedure (nine obtained at the time of BM harvest and five obtained 1 to 5 months before BM harvest). The myeloma Ig VH gene sequence was determined as previously described.34 Briefly, cDNA was created using Moloneymurine leukemia virus reverse transcriptase (GIBCO, Gaithersburg, MD), BM RNA and Ca or Cy consensus primers (constant-region a or y consensus primers). Because the VH gene sequences have been grouped into six families on the basis of sequence homology, the cDNA was aliquoted into six different reaction tubes. A consensus primer specific for one of the six VH gene familiess5 was then added and 32 cycles of PCR amplification were performed using Taq polymerase (Perkin Elmer Cetus, Norwalk, CT) and the hot start technique.36 This allowed for detection of the monoclonal VH gene product in most cases, yet does not yield a product using normal BM RNA. Detectable PCR product was excised from a low melt agarose gel and ligated into a pCR-Script SK(+) (Stratagene, La Jolla, CA) or pCR I1 (Invitrogen, San Diego, CA) vector. The PCR insert was then sequenced using the Sequenase I1 kit (US Biochemicals, Cleveland, OH) according to manufacturer's instructions with ''S a deoxyadenosine triphosphate (crdATP; Amersham, Arlington Heights, IL). To be certain that the sequence obtained was from the myeloma clone and not from normal plasma or B cells, a minimum of three identical sequences were needed. The myeloma VH gene sequence was then compared with known germline VH and JH gene^^^.'^ using the DNAsis program (Hitachi, San Bruno, CA). For use in the tumor detection assay, patient-specific oligonucleotide primers were prepared complementary to the most unique sequences in the CDRl or CDR2 (sense) and CDR3 (antisense).
PCR conditions. Sample DNA was isolated3' from an aliquot of the BM mononuclear sample described above, the CD34-selected autograft, and leukapheresis product before CD34 selection. DNA (0.6 pg = 100,000 cells) was amplified after the addition of SO pmol of each primer, 200 mmol/L of each deoxynucleotide, and 2.5 U of Taq polymerase in a final volume of 100 pL. Sixty cycles of the PCR were performed to increase the sensitivity of the assay. Fifteen microliters of the PCR product was then electrophoresed through a 1.6% agarose gel. The agarose gel was then soaked in SYBR green stain (CYBERGREEN Molecular Probes, Eugene, OR) for 60 minutes and PCR products were visualized by exposure to UV light. PCR conditions using the patient-specific primers were optimized for each patient using the PCR Optimizer kit (Invitrogen) with BM DNA serially diluted 1:10 with placental DNA and annealing temperatures of either 55°C or 60°C.
Tumor contamination assessment. Once the optimum annealing temperature and buffer composition were determined, all subsequent PCRs for that patient's samples were run under identical conditions. DNA from the sample (BM, leukapheresis, or CD34-selected product) was then serially diluted in 0.5-log increments with placental DNA to maintain a final DNA quantity of 0.6 Kg per reaction. Five replicate samples were processed at each serial dilution concentration and all reactions were done concurrently. Original sample contamination was then calculated based upon the Poisson distribution of positive reactions at each sample dilution?' Control PCR reactions were performed using 0.6 pg of sample DNA with @-actin primers (Stratagene).
Sensitivio of the PCR assay to detect tumor cells. The efficacy of the CEPRATE immunoadsorption column was assessed in 14 patients by comparing the degree of tumor contamination of the autograft product before and after CD34 selection. The Ig VH sequence of the myeloma cells was determined in each of these patients by reverse transcription PCR of BM RNA with a VH family and an Ig constant-region primer. We confirmed that the sequence obtained was from the myeloma cells because each PCR yielded product when only one of the six VH family primers was used (VHl, 4 patients; VH2, 1 patient; VH3, 7 patients; VH4, 1 patient; VHS, l patient). In addition, multiple clones (range, 3 to 6) were sequenced after insertion of the PCR product into a vector. These sequences were identical in every case and corresponded to the VH gene family identified in the initial PCR.
Oligonucleotide primers that were complementary to the CDR sequences were then designed for use in the tumor-detection PCR assay. These CDR primers should detect all malignant cells in a sample because the VH sequence lacks clonal diversity in multiple m y e l~m a . *~~*~ Tumor contamination was quantitated by the serial dilution of sample DNA with placental DNA in 0.5-log increments until product was no longer detectable by PCR amplification. Five replicate reactions were done at each serial dilution to improve assay sensitivity and improve the quantitative properties of the assay. Specificity was confirmed by the absence of product when placental or a different patient's leukapheresis DNA was substituted for sample DNA.
Under optimal conditions, the PCR should detect a single copy of the target gene after 40 cycles of PCR!' To maximize sensitivity, we increased the number of PCR cycles to 60 because this has occasionally increased our ability to detect the tumor VH gene product. Because quantitation of tumor contamination is not based on the relative intensity of the PCR band, but only on whether it is present or not in each tube, we wanted to assure that we would detect any amplified product with this technique. First, each PCR reaction was optimized using the patient's diluted BM sample with the PCR Optimizer kit (Invitrogen), which varies Mg+', pH conditions, and annealing temperatures. This was performed until the PCR amplified the greatest amount of VH product on serially diluted myeloma BM samples without additional nonspecific amplified PCR bands. Finally a more sensitive stain for DNA, SYBR Green, was used that identifies smaller quantities of the PCR product than ethidium bromide. By using these PCR conditions with the very specific CDR primers, we can detect one target gene copy within each PCR tube that contains DNA from 100,000 cells. Therefore, the likelihood of a PCR tube yielding a positive PCR result is based upon the presence of at least one target gene copy in the reaction mixture at that particular dilutional concentration. Because five reactions are done at each serial dilution, the Poisson distribution4' can then be applied to the positive PCR results from all of the serial dilutions for each sample to determine the percentage of tumor contamination in the undiluted BM, leukapheresis, or CD34-selected material.
To verify the validity of this technique, sample DNA from the myeloma IM-9 cell line4' was serially diluted with placental DNA to a total amount of 0.6 pg (DNA from =100,OOO cells) in 0.5-log increments. Using I"9-specific CDR primers, the IM-9 VH gene product was detectable in all sample reactions (S replicates at each dilution) when diluted s100,000-fold and in two reactions after 300,000-fold dilution. No product was detectable with further dilution. Therefore, the pure IM-9 cell line sample had a calculated tumor Contamination based upon Poisson distribution statistics which are within 0.22 log of the actual cell purity of the undiluted IM-9 cells. Myeloma cell contamination of the BM sample from the 14 patients analyzed in this study was calculated using this PCR assay and then compared with a cytospin of the same sample. These samples were obtained after the patients had received multiple courses of chemotherapy. Thus, BM contamination was low, and was calculated using Poisson distribution analysis to range from 0.1% to 5.4% in these patients using the PCR and Poisson distribution analysis. In all cases, these results closely matched the percentage of plasma cells identified by microscopic examination of these BM samples validating assay sensitivity and accuracy. Specifically, in the three cases with greater than 2% plasma cells, the calculated percentage from the PCR assay was within 0.3 log of the proportion determined by cytological examination. In the cases with 5 1% plasma cells, the percentage on the cytospins also closely matched the percentage determined by Poisson distribution analysis, although an exact logarithmic difference could not be assessed because of the infrequency of tumor cells in these latter specimens.
RESULTS
Overall response and survival. Thirty-seven patients with chemotherapy-responsive or stable multiple myeloma were entered into study; clinical characteristics are shown in Table 1 . Twenty-three were men and 14 were women. Paraproteins were detected in 33 of 37 patients: IgG in 27, IgA in 4, and light chains only in 2. At diagnosis, five patients were Durie-Salmon stage IA, 13 stage IIA, 13 stage IIIA, and six stage IIIB. Before treatment, 35 patients had lytic bone lesions or osteoporosis on radiographs. All patients had received chemotherapy and/or steroids before transplantation, which included infusional vincristine, doxorubicin, and oral dexamethasone (VAD) (l 1 patients), VAD plus alkylating agents (9 patients), alkylating agents (3 patients), dexamethasone alone (4 patients), and other treatments (10 patients).
Median duration of follow-up for surviving patients from the time of transplantation was 7.8 months (range, 1.4 to 14.5 months). Of 34 evaluable patients, complete and partial remissions were achieved in 5 (14.7%) and 28 (82.4%) respectively; one patient achieved a minimal response. Three patients have subsequently progressed and two have died (one on day +l39 and one on day +337). Disease stage, type of myeloma, and pretransplantation chemotherapy were analyzed and found to have no effect on response or progression-free survival. Actuarial progression-free and overall survival 1 year from transplantation are 67% +-19% and 68% -t-21%, respectively (Fig 1) .
Hematologic recovery and toxicity. A median of three collections (range, 2 to 5) was required to procure 9.8 X lo8 mononuclear cellskg (range, 3.7 to 28.3 X lo8 cellskg) and CD34% ranged from less than 1% to 15% (median 1%). A median of 5.9 X lo6 adsorbed cellskg (range, 1.6 X 10'kg to 25.5 X 106kg) and 4.65 X lo6 CD34 cellskg (range, 1.2 to 23.3 X 106kg) was obtained. CD34 purity after processing ranged from 27% to 91% (median, 77%). All 37 patients achieved neutrophil amounts greater than 0.5 X 109/L at a median of 12 days after transplantation (range, 11 to 16 days). Thirty-four patients achieved an untransfused platelet count greater than 20 X 109/L at a median of 12 days after transplantation (range, 9 to 52). Three patients did not achieve complete platelet recovery because of treatmentrelated mortality on days 28, 38, and 52. Three patients who achieved early platelet recovery developed late platelet transfusion-dependence because of infection, in two of whom infection and thrombocytopenia have now resolved. The median numbers of units of erythrocytes and platelets transfused to date are 7 (range, 2 to 37) and 3 (0 to SS), respectively. No patient required reinfusion of back-up BM. Six patients received fewer than 2 X lo6 CD34+ cellskg and had a statistically significantly increased red blood cell and platelet transfusion requirement, and a prolonged median time to platelet recovery (P = .005, P = .002, and P < .001, respectively) ( Table 2) .
There were five treatment-related deaths, one caused by viral pneumonia (day +38), two caused by hepatic venoocclusive disease (day +28 and day +52), two caused by late pulmonary toxicity attributed to the conditioning regimen (day +l77 and day +217). Other toxicities consisted of hemorrhagic cystitis (4 patients), and nonfatal interstitial pneumonitis (4 patients), nonfatal hepatic veno-occlusive disease (4 patients) and cardiac dysrhythmia (1 patient). Twenty-two of 37 patients developed mild to moderate (grades 1 to 2) mucositis, nausea and vomiting, and 9 patients had more severe (grades 3 to 4) gastrointestinal toxicity. Seven patients had nonfatal bacteremia.
Three patients sustained oral herpes simplex infection and one patient had infection with herpes zoster.
Purging effectiveness using CD34 selection. Because the sensitivity of the assay is 0.001% per reaction (1:1OO,OOO) and five replicate reactions are done at each concentration, the overall sensitivity of the PCR assay is 0.0002% (1:500,000). Before CD34 selection, tumor cells were detectable in the leukapheresis product in eight of 14 patients (Table 3) (Fig 2) . Calculated tumor contamination ranged from 0.23% to 0.0015% in these eight patients. Tumor contamination of the CD34-selected autograft product obtained from the same day as the leukapheresis sample was then assessed. Myeloma cell contamination remained detectable in only three of the 14 patients (Table 3) (Fig 2) . Moreover, CD34-selected autograft tumor cell contamination in these three patients was reduced (0.019%, 0.0030%, and 0.0005%) and the sample with the greatest contamination also had the highest initial contamination of the leukapheresis product before CD34 selection (0.23%). Positive controls using pactin primers with undiluted specimen DNA yielded the appropriately sized PCR product of similar band intensity in each case indicating that the sample DNA was of sufficient quality to permit PCR amplification.
The number of myeloma cells in the unselected leukapheresis product ranged from less than 1.60 X 103kg to 2.14 X 106kg (calculated by multiplying the percentage contamination by mononuclear cell numberkg). A minimum of 1.13 X io" multiple myeloma cells/kg were present in the leukapheresis products from the eight patients with detectable disease contamination. In the 14 patients analyzed, multiple myeloma contamination after CD34 selection ranged from less than 6 to 2 X lo3 cellskg. This reduction in tumor contamination after CD34-selection results from both the increased purity (ie, lack of tumor cells) of the autograft product and the median 2.2-log reduction in the total number of cells. In the 8 of 14 patients with detectable leukapheresis product myeloma contamination, the log reduction in autograft tumor contamination by the CD34-selection procedure ranged from more than 2.7 to more than 4.5 ( Table 4) .
DISCUSSION
Thirty-seven patients with multiple myeloma received pretransplantation conditioning with busulfan and cyclophosphamide followed by the infusion of CD34-selected peripheral blood progenitor cells. All patients were determined not to have chemotherapy-resistant disease because there was no evidence of progressive multiple myeloma from conventional chemotherapy given just before transplantation. Thus, conventional treatment was used to identify a group of patients likely to derive benefit from high-dose chemothe rap^.^ Patients who had received more than 1 year of alkylator-based chemotherapy were ineligible, regardless of response, because of concern over residual marrow function and impaired progenitor cell mobilization.I6 Peripheral blood progenitor cells were then purified by positive selection for the CD34 antigen. Mobilization was achieved via a combina- tion of chemotherapy, corticosteroids, and hematopoietic growth factor. Despite purification of these early progenitor cells and, thus, a marked decrease in the number of mononuclear cells infused, reconstitution of hematopoiesis was both rapid and complete. A threshold dose of 2 X IOh CD34' cellskg was defined, below which both transfusion support and engraftment were significantly prolonged. Complete and partial remissions were achieved in 33 of 34 evaluable patients (97%).
Using PCR analysis with patient-specific Ig-gene primers, we found tumor contamination in the leukapheresis specimens from more than half of the patients studied. Other investigators have also detected tumor cells in similar clinical specimens.'" However, the frequency of patients with contamination of leukapheresis products was lower using less sensitive tumor detection techniques. The use of Poisson distribution analysis of multiple PCR reactions allows for a much more sensitive and accurate assessment of tumor burden. Using this technique. we showed a marked (>2.7-to >4.5-log) reduction in the total number of tumor cells after CEPRATE-CD34 selection of these clinical leukapheresis specimens. These findings suggest that CD34' selection of peripheral blood progenitor cells produces a product that the concept that malignant cells in multiple myeloma do not express the CD34 antigen; this was previously shown in five patients with advanced multiple myeloma.34 An initial collection of CD34' cells was obtained by passage of BM mononuclear cells through the CEPRATE LC34-BIOTIN system. In comparison with the starting sample, this process reduced the concentration of tumor cells by 1.5 to 2.5 logs when assayed using DNA PCR with patient-specific CDR primers. When these cells were further purified using fluorescence-activated cell sorting, no residual myeloma could be detected, thus confirming that CD34+ cells are not part of the malignant plasma cell clone.
Other forms of BM or peripheral blood progenitor cell purification are less feasible for use in transplantation for multiple myeloma. No single antigen has been identified that is specific for the malignant cells. Consequently, the negative selection of tumor cells by means of antibody-purging requires a panel of MoAbs to be successful and may still fail to identify all malignant cells.12 The low rate of plasma cell replication makes the elimination of malignant cells in the autograft by exposure to cytotoxic agents problematic. Furthermore, extensive exposure to previous chemotherapy may render any form of chemotherapy purging hazardous because of a well-recognized risk of delayed
In the treatment of multiple myeloma, prolonged pancytopenia has been noted with 4-hydroperoxycyclophosphamide" and in both studies using MoAb purging of auto graft^,'^'^' with median times to neutrophil engraftment of 19, 21, and 25 days, respectively. Therefore, because of the inherent methodologic difficulties of antibody purging, and the risks associated with in vitro exposure to cytotoxic agents, we chose to purify peripheral blood progenitor cells by positive selection. The procedure, which yielded an average of 4.65 X IO6 CD34' cellskg, produced a progenitor cell material capable of rapid engraftment, with a median time to neutrophil and platelet recovery of 12 days after infusion.
The l-year progression-free survival in our study was 67% ? 19%, a very encouraging result, but one that will require prolonged follow-up given the group of patients studied, which consisted of patients with chemotherapy-responsive intermediate-to high-stage multiple myeloma. Studies of dose-intensive therapy in similar chemotherapy-sensitive multiple myeloma patients followed by transplantation of both purged and unpurged autologous BM or stem cells have shown similar
In conclusion, peripheral blood progenitor cells are an effective form of purified hematopoietic support achieving substantial reduction in myeloma cell contamination. At infused cell doses of greater than 2 X lo6 CD34' cellskg, this product provides safe, rapid, and sustained hematologic recovery in patients receiving myeloablative chemotherapy. Whether this form of purified stem cell support will produce improved progression-free survival in multiple myeloma will require further trials. A multi-institutional phase I11 study comparing CD34 selected versus unselected PBPC transplantation as treatment of multiple myeloma has been initiated to answer this question.
